Pin your most used calculators here by clicking the star in the dropdown.
Myeloma Master Panel (R2-ISS & Frailty)
Clinical Context & Background
This master calculator synthesizes the two critical pillars of Multiple Myeloma decision-making: Disease Biology and Patient Physiology.
1. Disease Biology: R2-ISS (2022)
The Second Revision of the International Staging System is the current standard for prognostic stratification. It improves upon the R-ISS by incorporating 1q gain/amplification as an independent risk factor.
Formula: ISS Stage (0-1.5 pts) + LDH (1 pt) + High Risk Cytogenetics (1 pt) + 1q Gain (0.5 pts).
Max Score: 5 points.
2. Patient Physiology: IMWG Frailty Score
Determines "biological age" to guide dose intensity. It assesses functional status (ADL, IADL), Comorbidities (CCI), and Age.
Fit: Candidate for full-dose induction (e.g., Quadruplets) and ASCT.
Intermediate: Candidate for standard Triplets; ASCT requires careful evaluation.
Frail: Candidate for "Lite" regimens (e.g., DRd) or dose-attenuated Triplets.
Clinical Synthesis:
The tool cross-references these scores to suggest a treatment strategy (e.g., aggressive curative intent vs. disease control with toxicity minimization).
Reference Data
| Score System | Category / Stage | Clinical Implication |
|---|---|---|
| R2-ISS | Stage I (0 pts) | Low Risk (Median OS: NR) |
| R2-ISS | Stage II (0.5 - 1.0 pts) | Low-Intermediate (Median OS: ~109 mo) |
| R2-ISS | Stage III (1.5 - 2.5 pts) | Intermediate-High (Median OS: ~82 mo) |
| R2-ISS | Stage IV (3.0 - 5.0 pts) | High Risk (Median OS: ~42 mo) |
| IMWG Frailty | Fit (Score 0) | Full Dose Induction + ASCT |
| IMWG Frailty | Intermediate (Score 1) | Full or Modified Dose +/- ASCT |
| IMWG Frailty | Frail (Score ≥ 2) | Attenuated Dose; Generally No ASCT |
Evidence-based oncology decision support. Verify with clinical guidelines.